Telix Pharmaceuticals Ltd — Capital/Financing Update 2019

Jul 2, 2019

==> picture [142 x 79] intentionally omitted <==

==> picture [135 x 43] intentionally omitted <==

Title: Telix Pharmaceuticals and Grupo RPH Sign LATAM Manufacturing and Distribution Agreement

Date: 3[rd] July 2019

Program relevance: TLX591-CDx ([68] Ga-PSMA-11) for the imaging of prostate cancer with positron emission tomography (PET)

Synopsis:

Grupo RPH is a leading radiopharmaceutical company active in the Brazilian market. Telix and Grupo RPH have signed a master product distribution agreement that covers the manufacturing and distribution of Telix’s products, starting with TLX591-CDx (68Ga-PSMA-11 kit) for the imaging of prostate cancer with Positron Emission Tomography (PET). The agreement with Grupo RPH significantly extends Telix’s international reach and will support product portfolio commercialization in Latin America (LATAM).

Key Points for Investors:

• Grupo RPH is a leading distributor of nuclear medicine products in Brazil, with a dominant market share.

• As part of its nuclear medicine products business, Grupo RPH owns a cold kit manufacturing facility and will provide commercial-scale kit manufacturing for Telix clinical and commercial activity in LATAM.

• Grupo RPH has an excellent track record in working with local / regional health and regulatory authorities. Grupo RPH and Telix will collaborate to a achieve marketing authorization in Brazil for PSMA imaging.

• The agreement with Grupo RPH potentially serves as a manufacturing and distribution platform for Telix’s products in 15 countries in the LATAM region.

Page 1

==> picture [142 x 79] intentionally omitted <==

==> picture [135 x 43] intentionally omitted <==

Telix Pharmaceuticals and GRUPO RPH Sign LATAM Manufacturing and Distribution Agreement

Melbourne (Australia) and Porto Alegre (Brazil) – 3[rd] July 2019. Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced the appointment of Grupo RPH as contract manufacturer and product distribution partner for Brazil. The partnership will initially focus on TLX591-CDx ([68] Ga-PSMA-11) for the imaging of prostate cancer but the agreement is structured to be able to include other Telix products in the future.

Grupo RPH Managing Director, Rafael Madke stated, “Telix’s rapid growth over the past twelve months has been impressive, with a promising product portfolio for the Latin American market. With the strong position of Grupo RPH in Brazil and our extensive capability to manufacture and distribute nuclear medicine products, we aim to support Telix’s commercial objectives in a cost and operationally-effective way for our region".

Telix Pharmaceuticals VP Corporate Development, Ludovic Wouters, noted: “This partnership with Grupo RPH opens us a large and rapidly-growing market for gallium-68 based radiopharmaceuticals. We are delighted to be working work such a capable partner to bring our prostate imaging technology to the LATAM market, with the potential of other product collaborations in the future.”

The agreement grants exclusive right for the manufacturing and distribution of the TLX591Cdx ([68] Ga-PSMA-11) cold kit for the Brazilian market.

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX).

For more information visit www.telixpharma.com.

About GRUPO RPH Radiopharmacus S.A.

Operating since 2004, Grupo RPH commercially delivers eight different Cold Kits for Tc99m and Ga68 preparation for the Brazilian market. Grupo RPH is also the proud owner of the only private-owned fully GMP production facility in Brazil for nuclear medicine products. Grupo RPH’s products are sold throughout the whole Brazilian territory, serving nearly 400 customers on a daily basis. Grupo RPH is also a pioneer of the Centralized Radiopharmacy model in Brazil.

For more information visit http://gruporph.com.br/en/

Page 2

==> picture [142 x 79] intentionally omitted <==

==> picture [135 x 43] intentionally omitted <==

Telix Corporate Contact Dr Christian Behrenbruch Telix Pharmaceuticals Limited CEO Email: chris@telixpharma.com

Telix Investor Relations Lisa Wilson In-Site Communications Tel: +1 212 452 2793 Email: lwilson@insitecony.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “US Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. None of the products described in this release have obtained a marketing authorisation in Brazil or any other jurisdiction.

Page 3